

MYRIAD GENETICS INC  
Form 8-K  
December 23, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 22, 2008

**MYRIAD GENETICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction

of incorporation)

**0-26642**  
(Commission

File Number)  
**320 Wakara Way**

**Salt Lake City, Utah 84108**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

.. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

.. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: MYRIAD GENETICS INC - Form 8-K

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01 Other Events.**

On December 22, 2008, Myriad Genetics, Inc. ( Myriad ) issued a press release to announce the launch of its sixth molecular diagnostic product, Prezeon . Prezeon will be marketed to researchers and physicians to assist them in understanding the status of the PTEN gene. The PTEN gene has been shown to be involved in many cancers, including cancer of the prostate, breast, colon, lung, brain, skin, uterus, kidney, bladder, blood, ovary and lymphatic system. The test is designed to provide information to help determine the most effective chemotherapy treatment for patients. The price per Prezeon test is \$500.

A copy of the press release announcing the launch is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into Item 8.01 of this Current Report on Form 8-K.

**ITEM 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Number</b>	<b>Description</b>
99.1	Press Release dated December 22, 2008.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MYRIAD GENETICS, INC.**

Date: December 23, 2008

By: /s/ Peter D. Meldrum  
Peter D. Meldrum  
President and Chief Executive Officer

Page 3 of 4 pages

EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated December 22, 2008.

Page 4 of 4 pages